CN115348854A - Curable compositions and methods of using curable compositions - Google Patents

Curable compositions and methods of using curable compositions Download PDF

Info

Publication number
CN115348854A
CN115348854A CN202180025588.4A CN202180025588A CN115348854A CN 115348854 A CN115348854 A CN 115348854A CN 202180025588 A CN202180025588 A CN 202180025588A CN 115348854 A CN115348854 A CN 115348854A
Authority
CN
China
Prior art keywords
curable composition
meth
composition
acrylate
curable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180025588.4A
Other languages
Chinese (zh)
Other versions
CN115348854B (en
Inventor
阿曼达·K·莱昂内
艾哈迈德·S·阿卜挨利亚曼
王一中
韦恩·S·马奥尼
威廉·H·莫泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of CN115348854A publication Critical patent/CN115348854A/en
Application granted granted Critical
Publication of CN115348854B publication Critical patent/CN115348854B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2/00Processes of polymerisation
    • C08F2/46Polymerisation initiated by wave energy or particle radiation
    • C08F2/48Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/80Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/84Preparations for artificial teeth, for filling teeth or for capping teeth comprising metals or alloys
    • A61K6/844Noble metals
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/10Esters
    • C08F222/1006Esters of polyhydric alcohols or polyhydric phenols
    • C08F222/102Esters of polyhydric alcohols or polyhydric phenols of dialcohols, e.g. ethylene glycol di(meth)acrylate or 1,4-butanediol dimethacrylate
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/10Esters
    • C08F222/1006Esters of polyhydric alcohols or polyhydric phenols
    • C08F222/103Esters of polyhydric alcohols or polyhydric phenols of trialcohols, e.g. trimethylolpropane tri(meth)acrylate
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00Use of inorganic substances as compounding ingredients
    • C08K3/02Elements
    • C08K3/08Metals
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00Use of inorganic substances as compounding ingredients
    • C08K3/02Elements
    • C08K3/08Metals
    • C08K2003/0806Silver

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dental Preparations (AREA)

Abstract

The curable composition comprises at least one monomer comprising at least one (meth) acryloyl group and a photoinitiator system. The photoinitiator system comprises at least one type II photoinitiator and at least one cyclic beta-diketone represented by formula (I)
Figure DDA0003870259540000011
Or a tautomer thereof. R 1 Denotes an organic moiety having at least one free-radically polymerizable group. Each R 2 Independently of each otherRepresents H or an aliphatic group having from 1 to 12 carbon atoms and up to two of the atoms oxygen and sulfur, and n represents 1,2 or 3.

Description

Curable compositions and methods of using curable compositions
Technical Field
The present disclosure relates broadly to curable compositions comprising a beta-diketone and a type II photoinitiator.
Background
Photo-initiated curing is used to produce many industrially important materials such as, for example, coatings, adhesives, restoratives, and sealants. The photo-initiated curing materials typically contain type I and/or type II photoinitiators. In each case, the application of light induces rapid curing. When irradiated with the correct wavelength, the type I photoinitiator fragment generates polymer-initiated free radicals. Type II photoinitiators can abstract H atoms upon absorption of light, thereby generating initiating free radical species. However, if there is no readily abstractable H-atom, then no initiation occurs.
For this reason, type II photoinitiators are usually paired with coinitiators having an abstractable H-atom to form a photoinitiator system. Common coinitiators are amine-based. However, in the presence of oxygen, amine-based co-initiators can oxidize and disadvantageously discolor the resulting material over time. In addition, amine-based co-initiators are typically acid sensitive, limiting their utility when acidic adhesion promoting monomers are in the polymerizable composition. In addition, excess or unused co-initiator may migrate and/or leach out of the cured composition over time.
Disclosure of Invention
Advantageously, the present inventors have found that certain non-amine based co-initiators having polymerizable (meth) acrylate functionality that can be used with acidic monomers can avoid amine based discoloration and polymerize into the polymer network during curing.
In one aspect, the present disclosure provides a curable composition comprising:
at least one monomer comprising at least one (meth) acryloyl group; and
a photoinitiator system comprising:
at least one cyclic beta-diketone of the formula
Figure BDA0003870259530000021
Or a tautomer thereof, wherein:
R 1 represents an organic moiety having at least one free-radically polymerizable group;
each R 2 Independently represents H or an aliphatic group having from 1 to 12 carbon atoms and up to two of the atoms of oxygen and sulfur; and is
n represents 1,2, or 3; and
at least one type II photoinitiator.
In some embodiments, the curable composition may be a curable dental composition that can be at least partially cured to provide, for example, a dental restorative composition or a dental adhesive composition.
The curable composition according to the present disclosure may be contacted with at least one substrate; and receiving sufficient actinic electromagnetic radiation to at least partially cure them.
As used herein:
the term "type II photoinitiator" refers to a compound in which absorption of electromagnetic radiation (e.g., ultraviolet and/or visible light) causes an excited electronic state in the type II photoinitiator that will extract hydrogen from the co-initiator and generate a free radical pair in the process.
The term "dental composition" refers to any composition that can be used in the dental field. By "dental composition" is meant an unfilled or filled (e.g., composite) material (e.g., dental or orthodontic material) capable of being applied or adhered to an oral surface. Dental compositions include, for example, adhesives (e.g., dental and/or orthodontic adhesives), cements (e.g., glass ionomer cements, resin-modified glass ionomer cements, and/or orthodontic cements), primers (e.g., orthodontic primers), restoratives (e.g., restorative filling materials), liners, sealants (e.g., orthodontic sealants), and coatings. Dental compositions are often used to bond dental articles to dental structures.
The term "substantially free" with respect to a component (e.g., an amine or metal chelate) means that the composition is free of the component as an essential feature. Thus, the components are not intentionally added to the composition by themselves or in combination with other components or ingredients of other components. Compositions that are substantially free of a component (e.g., resin) typically comprise the component in an amount of less than about 5 wt.%, less than about 1 wt.%, less than about 0.5 wt.%, or less than about 0.01 wt.%, based on the total weight of the composition or material. The composition may not comprise said components at all. However, the presence of a small amount of the component is sometimes unavoidable, for example, because of impurities contained in the raw materials used.
The term "(meth) acryl" is a shorthand term which refers to "acryl" and/or "methacryl". For example, a "(meth) acryloyloxy" group is a shorthand term referring to an acryloyloxy group (i.e., CH) 2 = CH-C (O) -O-) and/or a methacryloxy group (i.e. CH 2 =C(CH 3 )-C(O)-O-)。
The term "substituted" means that the hydrogen atom is replaced with another organic (e.g., alkyl, aryl, alkaryl, or aralkyl) or inorganic group (e.g., halide, hydroxyl, alkoxy); and is
The term "metal chelate" refers to a compound that is interposed between an organic moiety and a metal ion, wherein the metal ion has a formal charge of at least 2 +.
The features and advantages of the present disclosure will be further understood upon consideration of the detailed description and appended claims.
Detailed Description
Curable compositions according to the present disclosure comprise at least one monomer comprising at least one (meth) acryloyl group and a photoinitiator system. In many preferred embodiments, at least one monomer comprises at least two or at least 3 monomers comprising at least one (meth) acryloyl group.
In many embodiments of the present disclosure, monomers containing methacryloyl groups are preferred over those having acryloyl groups, although this is not required. In many embodiments, the polymerizable component preferably comprises one or more di-, tri-, tetra-and/or pentafunctional monomeric or oligomeric aliphatic, cycloaliphatic and/or aromatic (meth) acrylates.
The (meth) acryloyl group containing monomers are widely commercially available; for example, from Sartomer co, exton, pennsylvania and other suppliers. Suitable monomers may include mono (meth) acrylates, di (meth) acrylates, poly (meth) acrylates such as, for example, 2- (2-ethoxyethoxy) ethyl (meth) acrylate, 2-ethylhexyl (meth) acrylate, 2-hydroxyethyl (meth) acrylate, alkoxylated tetrahydrofurfuryl (meth) acrylate, allyl (meth) acrylate, bis [1- (2-acryloyloxy) ] -p-ethoxyphenyldimethyl methane, bis [1- (3-acryloyloxy-2-hydroxy) ] -p-propoxyphenyldimethyl methane, bis (trimethylolpropane) tetraacrylate, chlorinated polyester (meth) acrylate, diethylene glycol di (meth) acrylate, diglycidyl (meth) acrylate of bisphenol A, dodecyl (meth) acrylate, epoxide (meth) acrylate oligomers, ethoxylated or propoxylated glycerol tri (meth) acrylate, ethyl (meth) acrylate, ethylene glycol di (meth) acrylate, glycerol tri (meth) acrylate, hexanediol di (meth) acrylate, hexyl (meth) acrylate, hydroxybutyl (meth) acrylate, butyl (meth) acrylate, hydroxy-functional caprolactone (meth) acrylate, hydroxyisopropyl (meth) acrylate, hydroxymethyl (meth) acrylate, hydroxypropyl (meth) acrylate, isobornyl (meth) acrylate, isobutyl (meth) acrylate, isodecyl (meth) acrylate, isononyl (meth) acrylate, isooctyl (meth) acrylate, isopropyl (meth) acrylate, lauryl (meth) acrylate, methyl (meth) acrylate, n-butyl (meth) acrylate, neopentyl glycol di (meth) acrylate, n-hexyl (meth) acrylate, nonylphenol ethoxylate (meth) acrylate, octyl (meth) acrylate, pentaerythritol tetra (meth) acrylate, pentaerythritol triacrylate, poly (ethylene glycol) di (meth) acrylate, polybutadiene di (meth) acrylate, polyester (meth) acrylate oligomer, polyurethane di (meth) acrylate, siloxane (meth) acrylate oligomer, sorbitol hexyl acrylate, stearyl (meth) acrylate, tetraethylene glycol di (meth) acrylate, tetratetetrahydrofurfuryl (meth) acrylate, triethylene glycol di (meth) acrylate, tris (hydroxyethyl) isocyanurate, tris (meth) isocyanurate, beta-carboxyethyl (meth) acrylate, 1,1,1-trimethylolpropane tri (meth) acrylate, 1,2,4-butanetriol tri (meth) acrylate, hexane-2,4,6-triol tri (meth) acrylate, 1,3-propanediol di (meth) acrylate, 1,4-cyclohexanediol diacrylate, 1,6-hexanediol di (meth) acrylate, 1,12-dodecanediol di (meth) acrylate, (meth) acrylamide, N-dimethyl (meth) acrylamide, methylene bis- (meth) acrylamide, diacetone (meth) acrylamide, and combinations thereof.
The monomer containing at least one (meth) acryloyl group is typically present in the composition in an amount of at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 95, or even at least 98 weight percent based on the total weight of the composition, although this is not required.
The free radically polymerizable compound may comprise an acid functional monomer, where the acid functional group may be the acid itself (such as a carboxylic acid), or a portion may be a salt thereof (such as an alkali metal carboxylate). Useful acid functional monomers include, but are not limited to, those selected from ethylenically unsaturated carboxylic acids, ethylenically unsaturated sulfonic acids, ethylenically unsaturated phosphonic or phosphoric acids, and mixtures thereof. Examples of such compounds include those selected from the group consisting of: acrylic acid, methacrylic acid, itaconic acid, fumaric acid, crotonic acid, citraconic acid, maleic acid, oleic acid, beta-carboxyethyl (meth) acrylate, 2-sulfoethyl methacrylate, styrene sulfonic acid, 2-acrylamido-2-methylpropane sulfonic acid, vinyl phosphonic acid, phosphate esters of polypropylene glycol monomethacrylate, and mixtures thereof. Due to their availability, acid functional monomers are typically selected from ethylenically unsaturated carboxylic acids (e.g., (meth) acrylic acids). When a stronger acid is desired, the acidic monomers can include ethylenically unsaturated sulfonic acids and ethylenically unsaturated phosphonic acids. The acid functional monomer, if present, is generally used in an amount of from 0.5 to 15 parts by weight, preferably from 1 to 15 parts by weight, most preferably from 5 to 10 parts by weight, based on 100 parts by weight total monomer, but this is not required.
The photoinitiator system comprises at least one cyclic beta-diketone containing (meth) acrylate groups in combination with a type II photoinitiator.
Useful (meth) acrylate group-containing cyclic beta-diketones are represented by the formula
Figure BDA0003870259530000061
Or a tautomer thereof (e.g., as shown below):
Figure BDA0003870259530000062
wherein R is 1 Denotes an organic moiety having at least one free-radically polymerizable group.
In some preferred embodiments, R 1 Having from 4 to 32 carbon atoms and optionally containing from 1 to 12 atoms selected fromO, N and combinations thereof. In some preferred embodiments, R 1 Having from 4 to 20 carbon atoms and optionally containing from 1 to 10 heteroatoms selected from O, N and combinations thereof. In some preferred embodiments, R 1 Having from 4 to 16 carbon atoms and optionally containing from 1 to 8 heteroatoms selected from O, N and combinations thereof. In some preferred embodiments, R 1 Has 4 to 12 carbon atoms and optionally contains 1 to 8 heteroatoms selected from O, N and combinations thereof. In some preferred embodiments, R 1 Having from 4 to 8 carbon atoms and optionally containing from 1 to 6 heteroatoms selected from O, N and combinations thereof. Exemplary organic moieties R 1 Illustrated in the examples contained below.
In some preferred embodiments, R 1 Containing a single (meth) acryloyl group. In other preferred embodiments, R 1 Contains at least two (meth) acryloyl groups.
Each R 2 Independently represent H or an aliphatic group having from 1 to 12 carbon atoms (preferably from 1 to 8, more preferably from 1 to 4, and more preferably 1 or 2 carbon atoms) and up to two of the oxygen and sulfur atoms. In many preferred embodiments, R 2 Represents an alkyl group having 1 to 4 carbon atoms, more preferably a methyl or ethyl group.
n represents 1,2, or 3, more preferably 1 or 2.
Combinations of cyclic beta-diketones containing (meth) acrylate groups may also be used.
Cyclic beta-diketones containing (meth) acrylate groups can be prepared, for example, by (meth) acrylation of the corresponding alcohols according to known methods (e.g., using (meth) acryloyl chloride). Likewise, methods for preparing the corresponding alcohols are within the ability of those of ordinary skill in the art.
Suitable type II photoinitiators are well known in the art of photocuring. Commercially important type II photoinitiators include: diaryl ketones (e.g., benzophenone, 4-methylbenzophenone, or 4-chlorobenzophenone); 1-phenylpropane-1,2-dione (PPD); thioxanthone (2-isopropylthioxanthone, 2-mercaptothioxanthone, 2,4-Diethylthioxanthone (DETX), 1-chloro-4-propoxythioxanthone (CPTX) and 2-Chlorothioxanthone (CTX) or 4-isopropylthioxanthone); camphorquinone; biphenyl acyl; naphthoquinones (e.g., 2,2' -bis (3-hydroxy-1,4-naphthoquinone)), anthraquinones (e.g., anthraquinone, 1,4-dihydroxyanthraquinone, 2-methylanthraquinone, or 2,6-dihydroxyanthraquinone), and 3-coumarone or combinations thereof. Other type II Photoinitiators are described in Green, A.W. (2010), "Commercial Photoinitiators", industrial Photoinitiators, technical guides, pp.86-91, CRC Press, taylor and Francis Group (Commercial Photoinitiators, industrial Photoinitiators, A Technical Guide (pp.86-91), CRC Press, taylor and Francis Group).
The absorption characteristics of the type II photoinitiator will generally be selected based at least in part on the desired wavelength of actinic radiation selected. Typically, the actinic radiation will be in the ultraviolet (i.e., 200 nm to less than 400 nm) and/or visible (i.e., 400 nm to 700 nm) wavelength ranges, although this is not required. The preferred wavelength range is 250 nm to 450 nm.
The photoinitiator system may be used in any amount, preferably from 0.01 to 10 weight percent, more preferably from 0.1 to 5 weight percent, and more preferably from 0.1 to 2 weight percent, based on the total weight of the curable composition. The weight ratio of cyclic beta-diketone to type II photoinitiator will vary with the materials selected but is within the ability of one of ordinary skill in the art.
As previously mentioned, amines can produce aesthetically unacceptable discoloration over time. Thus, in many preferred embodiments, the curable composition is substantially free or free of organic amines. Likewise, the curable composition is preferably substantially free or free of beta-diketone (cyclic and/or acyclic) polyvalent metal complexes, which may also lead to coloration.
Curable compositions according to the present disclosure may contain silver (e.g., in the form of a silver salt, colloidal silver, or silver oxide). Examples of suitable silver salts include silver chloride, silver bromide, silver iodide, silver acetate, silver propionate, silver fluoride, silver nitrate, silver thiocyanate, silver fluoride diamine, silver iodide complex compounds, silver phosphate, or combinations thereof.
Compositions according to the present disclosure may contain a filler (i.e., one or more fillers). The filler may be selected to enhance certain characteristics such as compressive strength, radial tensile strength, abrasion resistance, appearance, translucency, radio opacity and storage stability of the dental material, as well as to limit exothermic effects during the initial curing stage. Optionally, to enhance the bond between the filler and the resin system, the surface of the filler particles may be treated with a surface treatment such as a silane coupling agent. The coupling agent may be functionalized with reactive curing groups such as acrylates and/or methacrylates. The filler may be selected from one or more of a variety of materials suitable for incorporation in compositions for dental applications, such as, for example, fillers currently used in dental restorative compositions.
The filler may be an inorganic material. Examples of suitable inorganic fillers include naturally occurring or synthetic materials such as quartz, nitrides (e.g., silicon nitride), glasses derived from, for example, ce, sb, sn, zr, sr, ba, or Al, colloidal silica, feldspar, borosilicate glass, kaolin, talc, titanium dioxide, zirconia and zinc glasses, zirconia-silica fillers; low mohs hardness fillers such as those described in U.S. Pat. No. 4,695,251 (Randklev); and submicron silica particles (e.g., fumed silica such as those available under the trade name "AEROSIL", such as "OX 50", "AEROSIL 130", "AEROSIL200", "AEROSIL 380" from Evonik, parsippany, new Jersey, usa, and "Cab-O-Sil M5" silica from Cabot corp., boston, massachusetts). Non-acid-reactive inorganic filler particles include quartz (i.e., silica), submicron silica, zirconia, submicron zirconia, and non-glass microparticles of the type described in U.S. Pat. No. 4,503,169 (Randklev). The filler may be a crosslinked organic material that is insoluble in the polymerizable resin, and is optionally filled with an inorganic filler. The filler is generally non-toxic and suitable for use in the mouth. The filler may be radiopaque, radiolucent, or non-radiopaque. Fillers used in dental applications are typically ceramic in nature.
The filler may also be an acid-reactive filler. Suitable acid-reactive fillers include metal oxides, glasses, and metal salts. Typical metal oxides include barium oxide, calcium oxide, magnesium oxide, and zinc oxide. Typical glasses include borate glasses, phosphate glasses, and untreated or silanol-treated fluoroaluminosilicate ("FAS") glasses. When placed in the oral environment, FAS glass has the added benefit of releasing fluoride at the dental treatment site. The FAS glass typically contains sufficient elutable cations such that when the glass is mixed with the components of the hardenable composition, a hardened dental composition will be formed. The glass also typically contains sufficient elutable fluoride ions so that the hardened composition will have cariostatic properties. The glass may be prepared from a melt containing fluoride, alumina and other glass forming ingredients using techniques familiar to those skilled in the art of FAS glass manufacture. FAS glasses are typically in the form of particles that are sufficiently finely divided so that they can be conveniently mixed with other cement components and the resulting mixture works effectively when used in the mouth.
Generally, the average particle size (typically referred to as diameter) of the FAS glass is no greater than 12 microns, typically no greater than 10 microns, and more typically no greater than 5 microns, as measured using, for example, a sedimentation particle size analyzer. Suitable FAS glasses will be familiar to those skilled in the art, are available from a variety of commercial sources, and many are found in currently available glass ionomer cements, such as those commercially available under the following trade names: VITREMER, VITREBOND, RELYX LUTING CEMENT, RELYX LUTING PLUS CEMENT, PHOTOAC-FIL QUICK, KETAC-MOLAR, and KETAC-FIL PLUS (3M ESPE Dental products, st. Paul, minnesota), FUJI II LC and FUJI IX (Tokyo GC Corporation, tokyo, japan)), and CHEMFIL Superior (Dentsply International, york, pennsylvania, of York, yonsylvania, york, yongpo, minn.). Mixtures of fillers may be used if desired.
Other suitable fillers are disclosed in U.S. Pat. Nos. 6,387,981 (Zhang et al) and 6,572,693 (Wu et al), and PCT International publication No. WO 01/30305 (Zhang et al), U.S. Pat. No. 6,730,156 (Windisch et al), WO 01/30307 (Zhang et al), and WO 03/063804 (Wu et al). The filler components described in these references include nanoscale silica particles, nanoscale metal oxide particles, and combinations thereof. Nanofillers are also described in U.S. patent nos. 7,090,721 (Craig et al), 7,090,722 (Budd et al) and 7,156,911; and U.S. Pat. No. 7,649,029 (Kolb et al).
Examples of suitable organic filler particles include, for example, filled or unfilled powdered polycarbonate, polyepoxide, and poly (meth) acrylate. Common dental filler particles are quartz, submicron silica, and non-glassy microparticles of the type described in U.S. Pat. No. 4,503,169 (Randklev).
Mixtures of these fillers as well as combination fillers made of organic and inorganic materials may also be used.
The filler may be particulate or fibrous in nature. The particulate filler may be generally defined as having an aspect ratio or aspect ratio of 20. A fiber can be defined as having an aspect ratio of greater than 20, or more commonly greater than 100. The shape of the particles may vary from spherical to ellipsoidal, or more planar, such as flakes or discs. The macroscopic properties may be highly dependent on the shape of the filler particles, and in particular the uniformity of the shape. Suitable optional fillers can be finely divided into particles having an average particle size (i.e., the longest dimension of the particle, such as the diameter) of no greater than about 10 microns and a maximum particle size of no greater than about 50 microns, although this is not required. The filler can have a unimodal or multimodal (e.g., bimodal) particle size distribution.
In some preferred embodiments, the dental composition comprises silica nanoparticles. Suitable nanosilicas are commercially available under the trade name NALCO COLLOIDAL silica from NALCO Chemical co, naperville, illinois. For example, preferred silica particles may be obtained using NALCO products 1040, 1042, 1050, 1060, 2327 and 2329.
The silica particles are preferably made from an aqueous colloidal dispersion of silica (i.e., a sol or hydrosol). The concentration of colloidal silica in the silica sol is typically about 1 to 50 weight percent. Colloidal silica sols that can be used are commercially available, having different colloidal sizes, see Matijevic, e.surface & Colloid Science, vol.6, ed., wiley John Sons,1973 (Matijevic, e., "surface and Colloid Science, vol.6, john wil international publishing company, 1973). Preferred silica sols for use in preparing the filler are provided as dispersions of amorphous silica in an aqueous medium, such as Nalco colloidal silica manufactured by Nalco Chemical Company, and those sols having a low sodium concentration that can be acidified by mixing with a suitable acid, such as LUDOX colloidal silica manufactured by dupont de Nemours & co or Nalco 2326 from Nalco Chemical Company. Preferably, the silica particles in the sol have an average particle size of about 5 to 100 nanometers (nm), more preferably 10 to 50nm, and most preferably 12 to 40 nm.
In some embodiments, the dental composition comprises zirconia nanoparticles. Suitable nanoscale zirconia nanoparticles can be prepared using hydrothermal techniques as described in U.S. Pat. No. 7,241,437 (Davidson et al).
In some embodiments, the total amount of filler is from about 2% to about 90% by weight, based on the total weight of the components of the dental material. In certain embodiments, the total amount of filler is from about 30% to about 85% by weight, based on the total weight of the components of the dental material. The optional filler can be present in any suitable amount (e.g., 10 to 90 weight percent of the curable composition, preferably 10 to 60 weight percent of the curable composition).
Curable compositions according to the present disclosure may comprise one or more additional components such as, for example, solvents, antioxidants, flavoring agents, fluorinating agents, buffering agents, numbing agents, remineralizing agents, desensitizing agents, coloring agents, indicators, viscosity modifiers, surfactants, stabilizers, preservatives (e.g., benzoic acid), or combinations thereof.
The curable composition according to the present disclosure may be used as a dental composition. The dental composition is typically a hardenable composition that can be hardened at ambient conditions including a temperature range of about 15 ℃ to 50 ℃ or about 20 ℃ to 40 ℃ in a time range of about 30 minutes or 20 minutes or 10 minutes or 1 minute or less. Higher temperatures are not recommended because they may cause pain to the patient and may be harmful to the patient's health. Dental compositions are typically provided to practitioners in comparably small volumes, i.e. volumes in the range of about 0.1ml to about 100ml or about 0.5ml to about 50ml or about 1ml to 30 ml. Thus, the storage volumes of the available packaging units are within these ranges.
Curable compositions according to the present disclosure may be applied to at least one substrate and then cured using actinic radiation. Exemplary radiation sources include LED lamps (e.g., at 365nm, 385nm, 405nm, or 450 nm), arc lamps (e.g., hg or Xe arc lamps), flash lamps (e.g., xe flash lamps), ultraviolet or visible wavelength lasers (e.g., excimer, solid-state, pulsed, and/or CW lasers), and microwave-driven type H, D, or V mercury lamps (e.g., sold by Heraeus Noblelight America, gaithersburg, maryland). Filters and/or dichroic mirrors, for example, may also be used to reduce the thermal energy associated with the actinic radiation. The selection of curing conditions is within the ability of one of ordinary skill in the art.
Exemplary substrates may comprise metal, glass, ceramic, wood, plastic, fiber composites, enamel and/or dentin, and combinations thereof.
Selected embodiments of the present disclosure
In a first embodiment, the present disclosure provides a curable composition comprising:
at least one monomer comprising at least one (meth) acryloyl group; and
a photoinitiator system comprising:
at least one cyclic beta-diketone of the formula
Figure BDA0003870259530000131
Or a tautomer thereof, wherein:
R 1 represents an organic moiety having at least one free-radically polymerizable group;
each R 2 Independently represents H or an aliphatic group having from 1 to 12 carbon atoms and up to two of the atoms of oxygen and sulfur; and is
n represents 1,2, or 3; and
at least one type II photoinitiator.
In a second embodiment, the present disclosure provides the curable composition of the first embodiment, wherein the curable composition does not contain an organic amine.
In a third embodiment, the present disclosure provides the curable composition of the first or second embodiment, wherein the curable composition is free of at least one polyvalent metal complex of a cyclic β -diketone.
In a fourth embodiment, the present disclosure provides the curable composition of any one of the first to third embodiments, wherein the curable composition comprises silver.
In a fifth embodiment, the present disclosure provides the curable composition of any one of the first to fourth embodiments, further comprising a filler.
In a sixth embodiment, the present disclosure provides the curable composition of any one of the first to fifth embodiments, wherein the at least one type II photoinitiator comprises at least one of camphorquinone or isopropylthioxanthone.
In a seventh embodiment, the present disclosure provides the method according to any one of the first to sixth embodimentsThe curable composition of (1), wherein R 1 Having from 4 to 32 carbon atoms and optionally containing from 1 to 12 heteroatoms selected from O, N and combinations thereof.
In an eighth embodiment, the present disclosure provides the curable composition of any one of the first to seventh embodiments, wherein R 1 Having from 4 to 20 carbon atoms and optionally containing from 1 to 10 heteroatoms selected from O, N and combinations thereof.
In a ninth embodiment, the present disclosure provides the curable composition of any one of the first to eighth embodiments, wherein R 1 Containing a single free radical polymerizable group.
In a tenth embodiment, the present disclosure provides the curable composition of any one of the first to eighth embodiments, wherein R 1 Containing two free-radically polymerizable groups.
In an eleventh embodiment, the present disclosure provides a curable composition according to any one of the first to tenth embodiments, wherein the curable composition comprises a curable dental composition.
In a twelfth embodiment, the present disclosure provides a method of making an at least partially cured composition, the method comprising:
contacting the curable composition according to any one of the first to eleventh embodiments with at least one substrate; and
subjecting the curable composition to sufficient actinic electromagnetic radiation to provide the at least partially cured composition.
In a thirteenth embodiment, the present disclosure provides an at least partially cured composition made by the method according to the twelfth embodiment.
In a fourteenth embodiment, the present disclosure provides an at least partially cured composition according to the thirteenth embodiment, the at least partially cured composition herein comprising a dental composition.
Objects and advantages of this disclosure are further illustrated by the following non-limiting examples, but the particular materials and amounts thereof recited in these examples, as well as other conditions and details, should not be construed to unduly limit this disclosure.
Examples
All parts, percentages, ratios, and the like in the examples and the remainder of the specification are by weight unless otherwise indicated. Table 1 below reports the materials and light sources used in the examples.
TABLE 1
Figure BDA0003870259530000151
Figure BDA0003870259530000161
Synthesis of 2- (4-hydroxybenzyl) cyclohexane-1,3-Dione (DOH)
Figure BDA0003870259530000162
To a round bottom flask was added 1,3-cyclohexanedione (32.02g, 1.000 equivalents), 4-hydroxybenzaldehyde (34.85g, 1.000 equivalents), L-proline (13.15g, 0.4000 equivalents), and ethanol (1.428L). The reaction was stirred at room temperature for 45min. Then, naBH was added in 2g portions over 10 minutes 3 CN (17.95g, 1.000 equiv). The heterogeneous mixture was heated to 80 ℃ and stirred for 18 hours. Most of the ethanol was removed under reduced pressure to give an orange viscous oil, which was dissolved in ethyl acetate (200 mL), quenched with HCl solution (1m, 200ml) and stirred until bubbling ceased. The organic layer was separated and washed with HCl solution (1M, 3X 100 mL) and brine (2X 100 mL). The organic layers were collected, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure to give an orange oil which was crystallized from hot ethyl acetate (100 mL) to give DOH (25.9 g) as a pale orange solid.
Synthesis of 2- (((4- ((2,6-dioxocyclohexyl) methyl) phenoxy) carbonyl) amino) ethyl methacrylate (DCMA)
Figure BDA0003870259530000171
DOH (5.00g, 1.00 eq) was dissolved in dry tetrahydrofuran (60 mL) in a flask equipped with a stir bar and stirred for 2 minutes. Triethylamine (3.19mL, 1.00 equiv) was then added, and some precipitate formed. The mixture was stirred for an additional 2 minutes, then IEM (3.24mL, 1.00 equiv.) and BHT (224 mg) were added and stirred at room temperature for 60 minutes. The orange solution was then concentrated under room atmosphere overnight (18 hours) to give an orange viscous oil, which was purified by column chromatography using a gradient eluent from 80/20 to 20/80 hexane/ethyl acetate (v/v). The desired fractions were collected, BHT (10 mg) was added, and the solvent was removed under reduced pressure to give DCMA as a white powder (3.39 g).
Examples EX-1 to EX-13 and comparative examples CE-A to CE-G
For the examples in table 2, the materials were combined to produce the inventive and comparative examples in the table below. An aliquot of the formulation was placed on a glass slide, illuminated with a light source (specified in table 2), and immediately evaluated by poking with a wooden spatula to determine if the formulation had cured (hard, brittle solids), partially cured (gel formed) or remained uncured (liquid).
TABLE 2
Material EX-1 CE-A CE-B1 CE-B2 EX-2 CE-C
DCMA 1.2 0 1.2 1.5 2 0
SR339 33 36.8 33.5 34.6 38.2 34.7
SR350 64.3 61.9 65.3 63.9 59.1 64.7
ITX 1.5 1.3 - - - -
CPQ - - - - 0.7 0.6
365LED Is that Is that Is that - - -
Blue LED - - - Is that Is that Is that
Results Has been cured Not solidified Not cured Not cured Has already solidified Not cured
For the examples in tables 3 and 4, the materials were combined to produce the inventive and comparative examples in the following tables. An aliquot of the formulation was placed on a glass slide, illuminated with a blue LED light source (described in table 1), and immediately evaluated by poking with a wooden spatula to determine if the formulation had cured (hard, brittle solids), partially cured (gel formed) or remained uncured (liquid).
TABLE 3
Material CE-D CE-E EX-3 EX-4 EX-5 EX-6
DCMA 0.00 0.00 1.96 1.81 1.96 1.77
CPQ 0.24 0.24 0.23 0.22 0.23 0.21
EDMAB 0.40 0.48
HEMA 39.60 29.70 48.91 45.28
BisGMA 8.30 29.70 48.91 45.28 27.91 25.21
TEGDMA 3.60
GDMA 7.90
Procrylat K 55.81 50.43
DDDMA 13.96 12.61
BHT 0.14 0.13
AgI 12.44 12.38 2.30 3.00
NH 4 I 12.56 12.50 2.32 3.03
NH 4 F 1.96 1.95 0.36 0.47
Water (W) 13.08 13.01 2.42 3.15
Results Not cured Not cured Has already solidified Partially curing Has been cured Has been cured
TABLE 4
Figure BDA0003870259530000191
The preceding description, given to enable one of ordinary skill in the art to practice the claimed disclosure, is not to be construed as limiting the scope of the disclosure, which is defined by the claims and all equivalents thereto.

Claims (14)

1. A curable composition comprising:
at least one monomer comprising at least one (meth) acryloyl group; and
a photoinitiator system, the photoinitiator system comprising:
at least one cyclic beta-diketone of the formula
Figure FDA0003870259520000011
Or a tautomer thereof, wherein:
R 1 represents an organic moiety having at least one free-radically polymerizable group;
each R 2 Independently represent H or an aliphatic group having from 1 to 12 carbon atoms and up to two of the oxygen and sulfur atoms; and is
n represents 1,2, or 3; and
at least one type II photoinitiator.
2. The curable composition of claim 1, wherein the curable composition is free of an organic amine.
3. The curable composition of claim 1, wherein the curable composition is free of polyvalent metal complexes of the at least one cyclic beta-diketone.
4. The curable composition of claim 1, wherein the curable composition comprises silver.
5. The curable composition of claim 1, further comprising a filler.
6. The curable composition of claim 1, wherein the at least one type II photoinitiator comprises at least one of camphorquinone or isopropylthioxanthone.
7. The curable composition of claim 1, wherein R 1 Having from 4 to 32 carbon atoms and optionally containing from 1 to 12 heteroatoms selected from O, N and combinations thereof.
8. The curable composition of claim 1, wherein R 1 Has 4 to 20 carbon atoms, andand optionally containing 1 to 10 heteroatoms selected from O, N and combinations thereof.
9. The curable composition of claim 1, wherein R 1 Containing a single free radical polymerizable group.
10. The curable composition of claim 1, wherein R 1 Containing two free-radically polymerizable groups.
11. The curable composition of claim 1, wherein the curable composition comprises a curable dental composition.
12. A method of making an at least partially cured composition, the method comprising:
contacting the curable composition of claim 1 with at least one substrate; and
subjecting the curable composition to sufficient actinic electromagnetic radiation to provide the at least partially cured composition.
13. An at least partially cured composition prepared by the method of claim 12.
14. The at least partially cured composition of claim 13, wherein the at least partially cured composition comprises a dental composition.
CN202180025588.4A 2020-04-08 2021-04-05 Curable composition and method of using the curable composition Active CN115348854B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063006842P 2020-04-08 2020-04-08
US63/006,842 2020-04-08
PCT/IB2021/052823 WO2021205326A1 (en) 2020-04-08 2021-04-05 Curable compositions and methods of using the same

Publications (2)

Publication Number Publication Date
CN115348854A true CN115348854A (en) 2022-11-15
CN115348854B CN115348854B (en) 2024-09-10

Family

ID=75801631

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180025588.4A Active CN115348854B (en) 2020-04-08 2021-04-05 Curable composition and method of using the curable composition

Country Status (4)

Country Link
US (1) US20230119465A1 (en)
EP (1) EP4132452B1 (en)
CN (1) CN115348854B (en)
WO (1) WO2021205326A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985052A (en) * 2010-07-02 2013-03-20 3M创新有限公司 Dental composition, kit of parts and use thereof
CN103370041A (en) * 2011-02-15 2013-10-23 3M创新有限公司 Dental compositions comprising ethylenically unsaturated addition-fragmentation agent
WO2016014218A1 (en) * 2014-07-22 2016-01-28 3M Innovative Properties Company Free-radical polymerization methods and articles thereby
JP2016113438A (en) * 2014-12-18 2016-06-23 クラレノリタケデンタル株式会社 Dental curable composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695251A (en) 1980-04-07 1987-09-22 Minnesota Mining And Manufacturing Company Orthodontic bracket adhesive and abrasive for removal thereof
US4503169A (en) 1984-04-19 1985-03-05 Minnesota Mining And Manufacturing Company Radiopaque, low visual opacity dental composites containing non-vitreous microparticles
US6730156B1 (en) 1999-10-28 2004-05-04 3M Innovative Properties Company Clustered particle dental fillers
US6572693B1 (en) 1999-10-28 2003-06-03 3M Innovative Properties Company Aesthetic dental materials
US6387981B1 (en) 1999-10-28 2002-05-14 3M Innovative Properties Company Radiopaque dental materials with nano-sized particles
EP1586294B2 (en) 1999-10-28 2016-02-17 3M Innovative Properties Company Nano-sized silica particles in a dry powder form
AU2003209430B2 (en) 2002-01-31 2008-09-11 3M Innovative Properties Company Dental pastes, dental articles, and methods
JP4127104B2 (en) * 2002-04-03 2008-07-30 Dic株式会社 Photopolymerization initiator, novel compound and photocurable composition
US7649029B2 (en) 2004-05-17 2010-01-19 3M Innovative Properties Company Dental compositions containing nanozirconia fillers
US7090721B2 (en) 2004-05-17 2006-08-15 3M Innovative Properties Company Use of nanoparticles to adjust refractive index of dental compositions
US7090722B2 (en) 2004-05-17 2006-08-15 3M Innovative Properties Company Acid-reactive dental fillers, compositions, and methods
US7156911B2 (en) 2004-05-17 2007-01-02 3M Innovative Properties Company Dental compositions containing nanofillers and related methods
US7241437B2 (en) 2004-12-30 2007-07-10 3M Innovative Properties Company Zirconia particles
WO2008082881A1 (en) * 2006-12-28 2008-07-10 3M Innovative Properties Company (meth)acryloyl-containing materials, compositions, and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985052A (en) * 2010-07-02 2013-03-20 3M创新有限公司 Dental composition, kit of parts and use thereof
CN103370041A (en) * 2011-02-15 2013-10-23 3M创新有限公司 Dental compositions comprising ethylenically unsaturated addition-fragmentation agent
WO2016014218A1 (en) * 2014-07-22 2016-01-28 3M Innovative Properties Company Free-radical polymerization methods and articles thereby
JP2016113438A (en) * 2014-12-18 2016-06-23 クラレノリタケデンタル株式会社 Dental curable composition

Also Published As

Publication number Publication date
WO2021205326A1 (en) 2021-10-14
EP4132452B1 (en) 2024-05-29
US20230119465A1 (en) 2023-04-20
CN115348854B (en) 2024-09-10
EP4132452A1 (en) 2023-02-15

Similar Documents

Publication Publication Date Title
JP4638349B2 (en) Compositions and methods comprising polymerizable bisphosphonic acids
JP6077463B2 (en) Dental composition containing an ethylenically unsaturated addition cleavage agent
KR102008353B1 (en) Addition-fragmentation oligomers
CN102037024B (en) Photopolymerizable compositions
EP2976323B1 (en) High refractive index addition-fragmentation agents
EP3259323A1 (en) Addition-fragmentation oligomers
AU2015238582B2 (en) Dental composition
CN106132380B (en) Photopolymerizable dual-cure dental materials based on thiourea derivatives
US8455565B2 (en) Disulfide monomers comprising ethylenically unsaturated groups suitable for dental compositions
KR101712414B1 (en) Allyl disulfide-containing addition-fragmentation oligomers
TW201734122A (en) Redox polymerizable composition with photolabile transition metal complexes
JP6410803B2 (en) Trithiocarbonate-containing addition-cleavage agent
EP3370681A1 (en) Redox polymerizable dental composition with photolabile transition metal complexes
EP3107975A1 (en) Addition-fragmentation oligomers having high refractive index groups
CN115380053A (en) Curable compositions and methods of using curable compositions
EP3864002B1 (en) Addition-fragmentation agent with pendent amine groups
CN115348854B (en) Curable composition and method of using the curable composition
US8431626B2 (en) Disulfide monomers comprising ethylenically unsaturated norbornyl groups suitable for dental compositions
KR20160133482A (en) Monomer mixtures for producing dental materials
CN109843861B (en) Photoinitiators with protected carbonyl groups
JP3506564B2 (en) Dental photopolymerizable composition
JP2022529244A (en) Dental composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant